30 Jun
2022
05:00 E.S.T.

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

Read more

28 Jun
2022
16:30 E.S.T.

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Read more

28 Jun
2022
16:05 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

Read more

23 May
2022
16:30 E.S.T.

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022

Read more

16 May
2022
08:30 E.S.T.

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

Read more

12 May
2022
16:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

Read more

05 May
2022
16:30 E.S.T.

Cellectis to Report First Quarter 2022 Financial Results

Read more

05 May
2022
16:00 E.S.T.

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Read more

28 Apr
2022
08:00 E.S.T.

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Read more

27 Apr
2022
04:00 E.S.T.

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more